Sections
Title | Starting Page | Number of Pages |
---|
COVER | 1 | 4 |
PLUNKETT S BIOTECH &GENETICS INDUSTRY ALMANAC 2014 | 5 | 4 |
CONTENTS | 9 | 2 |
INTRODUCTION | 11 | 2 |
HOW TO USE THIS BOOK | 13 | 3 |
Chapter 1 MAJOR TRENDS AFFECTING THE BIOTECH &GENETICS INDUSTRY | 16 | 38 |
1) The State of the Biotechnology Industry Today | 17 | 5 |
2) A Short History of Biotechnology | 22 | 1 |
3) Ethanol Production Soared, But U.S. Federal Subsidy Expires | 23 | 3 |
4) Major Drug Companies Acquire or Partner with Smaller Biotech Firms | 26 | 1 |
5) From India to Singapore to China, Nations Compete Fiercely in Biotech Development | 27 | 2 |
6) Clinical Trials and Medical Records Processing Conducted Abroad Spark Concerns | 29 | 1 |
7) Gene Therapies and Patients Genetic Profiles Promise a Personalized Approach to Medicine | 29 | 2 |
8) Vaccines and Viruses in Drug Delivery | 31 | 1 |
9) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues/Research Focus Shifts | 32 | 3 |
10) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age | 35 | 1 |
11) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce | 36 | 1 |
12) Breakthrough New Drug Delivery Systems Evolve | 37 | 1 |
13) Stem Cells Multiple Sources Stem from New Technologies | 38 | 2 |
14) Government Support for New Stem Cell Research Evolves | 40 | 1 |
15) Stem Cells Therapeutic Cloning Techniques Advance | 41 | 1 |
16) Stem Cells A New Era of Regenerative Medicine Takes Shape | 42 | 2 |
17) Nanotechnology Converges with Biotech | 44 | 1 |
18) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise | 44 | 4 |
19) Focus on Vaccines | 48 | 1 |
20) Technology Discussion Genomics and Personal Gene Profiles | 49 | 1 |
21) Technology Discussion Proteomics | 50 | 1 |
22) Technology Discussion Microarrays | 50 | 1 |
23) Technology Discussion DNA Chips | 50 | 1 |
24) Technology Discussion SNPs ( Snips ) | 51 | 1 |
25) Technology Discussion Combinatorial Chemistry | 51 | 1 |
26) Technology Discussion Synthetic Biology | 51 | 1 |
27) Technology Discussion Recombinant DNA | 52 | 1 |
28) Technology Discussion Polymerase Chain Reaction (PCR) | 52 | 2 |
Chapter 2 BIOTECH &GENETICS INDUSTRY STATISTICS | 54 | 19 |
Biotech Industry Overview | 55 | 1 |
The U.S. Drug Discovery &Approval Process | 56 | 1 |
U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2012 | 57 | 1 |
U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2012 | 58 | 1 |
Employment in Life &Physical Science Occupations, U.S.: May 2012 | 59 | 1 |
Federal R&D &R&D Plant Funding for General Science &Basic Research, U.S.: Fiscal Years 2011-2013 | 60 | 1 |
U.S. Exports &Imports of Pharmaceutical Products: 2007-1st Quarter 2013 | 61 | 1 |
U.S. Prescription Drug Expenditures, Aggregate &Per Capita Amounts, Percent Distribution: 2006-2021 | 62 | 2 |
U.S. Prescription Drug Expenditures: 1970-2021 | 64 | 2 |
Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2012 | 66 | 1 |
Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2012-2014 | 67 | 1 |
Global Area of Biotech Crops by Country: 2012 | 68 | 1 |
Domestic &Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2012 | 69 | 1 |
Sales By Geographic Area, PhRMA Member Companies: 2011 | 70 | 1 |
Domestic U.S. Biopharmaceutical R&D &R&D Abroad, PhRMA Member Companies: 1975-2012 | 71 | 1 |
Domestic U.S. Biopharmaceutical R&D &R&D Abroad Breakdown, PhRMA Member Companies: 2011 | 72 | 1 |
Chapter 3 IMPORTANT BIOTECH &GENETICS INDUSTRY CONTACTS | 73 | 38 |
Chapter 4 THE BIOTECH 400: WHO THEY ARE AND HOW THEY WERE CHOSEN | 111 | 437 |
INDUSTRY LIST, WITH CODES | 112 | 1 |
INDEX OF COMPANIES WITHIN INDUSTRY GROUPS | 113 | 10 |
ALPHABETICAL INDEX | 123 | 4 |
INDEX OF U.S. HEADQUARTERS LOCATION BY STATE | 127 | 3 |
INDEX OF NON-U.S. HEADQUARTERS LOCATION BY COUNTRY | 130 | 2 |
Individual Profiles On Each Of THE BIOTECH 400 | 132 | 416 |
ADDITIONAL INDEXES | 548 | 24 |
INDEX OF FIRMS NOTED AS HOT SPOTS FOR ADVANCEMENT FOR WOMEN &MINORITIES | 549 | 2 |
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS | 551 | 21 |
A Short Biotech &Genetics Industry Glossary | 572 | 21 |